PCA
UTHR icon

Pallas Capital Advisors’s United Therapeutics UTHR Stock Holding History

Pallas Capital Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.21M Sell
2,227
-84
-4% -$47.3K 0.04% 310
2026
Q1 		$1.37M Sell
2,311
-1,790
-44% -$891K 0.05% 264
2025
Q4 		$2M Buy
4,101
+2,445
+148% +$1.14M 0.07% 219
2025
Q3 		$694K Sell
1,656
-177
-10% -$59.5K 0.03% 431
2025
Q2 		$527K Buy
1,833
+693
+61% +$207K 0.02% 488
2025
Q1 		$351K Sell
1,140
-652
-36% -$223K 0.01% 561
2024
Q4 		$632K Sell
1,792
-103
-5% -$37.9K 0.03% 320
2024
Q3 		$664K Buy
1,895
+729
+63% +$246K 0.03% 297
2024
Q2 		$383K Buy
1,166
+175
+18% +$46.3K 0.02% 360
2024
Q1 		$228K Buy
+991
New +$224K 0.01% 394

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Pallas Capital Advisors's UTHR Position: Q2 2026 in Review

Pallas Capital Advisors reduced its United Therapeutics (UTHR) stake by 3.6% in Q2 2026, selling an estimated $47.3K and leaving 2,227 shares worth $1.21M. The position accounts for 0.04% of the portfolio, ranked #310.

Pallas Capital Advisors first reported a position in UTHR in Q1 2024 and has held it in 10 quarters since. The position peaked at $2M in Q4 2025. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Pallas Capital Advisors held 2,227 shares of United Therapeutics worth $1.21M as of Q2 2026.
  • Pallas Capital Advisors sold 84 United Therapeutics shares in Q2 2026, an estimated $47.3K.
  • United Therapeutics made up 0.04% of Pallas Capital Advisors's portfolio in Q2 2026, its #310 holding.
  • Pallas Capital Advisors first reported a position in United Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Pallas Capital Advisors's United Therapeutics position peaked at $2M in Q4 2025.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.